December 17, 2020

The Honorable Stephen M. Hahn
Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD  20993
Stephen.Hahn@fda.hhs.gov

RE: Scientific Support for Granting Citizen Petition Urging Prohibition of Menthol as Characterizing Flavor in Cigarettes (FDA-2013-P-0435-0001)

Dear Commissioner Hahn:

As scientific experts in the fields of tobacco use and addiction, we are writing to urge the Food and Drug Administration (FDA) to grant the Citizen Petition urging prohibition of menthol as a characterizing flavor in cigarettes. It has come to our attention that in response to a lawsuit pending in federal court in the Northern District of California,1 FDA’s Center for Tobacco Products “has agreed to provide a final response to Plaintiffs’ citizen petition by January 29, 2021.”2 For an agency committed to science-based decision-making, the only defensible decision based on available evidence is to prohibit menthol as a characterizing flavor in cigarettes.

In 2011, the FDA’s Tobacco Products Scientific Advisory Committee (TPSAC) concluded that, “Removal of menthol cigarettes from the marketplace would benefit the public health in the United States.” In 2013, FDA’s Preliminary Scientific Evaluation of the Possible Public Health Effects of Menthol versus Nonmenthol Cigarettes (FDA Report) reached the conclusion, consistent with TPSAC’s, that it is “likely that menthol cigarettes pose a public health risk above that seen with nonmenthol cigarettes.”3 The TPSAC Report projected the adverse impact of menthol in cigarettes from 2011 to the present day, finding that “by 2020, about 17,000 premature deaths will occur and about 2.3 million people will have started smoking, beyond what would have occurred absent availability of menthol cigarettes.”4 In the years since these reports, the science supporting menthol’s role in increasing youth initiation and addiction, reducing cessation, and perpetuating health disparities, has only grown.

We could not agree more with the statement in your recent commentary in the New England Journal of Medicine - “It’s time we recognize smoking for what it is — our country’s longest-running and deadliest epidemic — and treat it with a commensurate sense of urgency.”5 Given the tremendous burden of tobacco use, and particularly the use of menthol cigarettes, on the nation’s health, it is imperative that FDA grant the Citizen Petition.

---

2 Federal Defendants’ Memorandum in Support of Motion to Dismiss, AATCLC v. HHS (Sept. 18, 2020), at 1, n.1.
The Role of Menthol in Youth Smoking Initiation and Transition to Regular Smoking

Due to its analgesic properties, the use of menthol as a characterizing flavor in cigarettes masks the harshness of tobacco smoke, making it easier for new users – particularly tobacco naïve youth – to initiate smoking. The undersigned researchers concur with the conclusions of both the TPSAC report and FDA’s own analysis, which determined that menthol cigarettes increase smoking initiation, youth addiction, and progression to regular smoking.

Data from the National Survey on Drug Use and Health (NSDUH) shows that preference for menthol cigarettes is inversely correlated with age. According to both NSDUH and the National Youth Tobacco Survey (NYTS), about half of youth smokers use menthol cigarettes. 2017 and 2018 NYTS data also show that among middle and high school students, smoking of menthol cigarettes is associated with greater smoking frequency and intention to continue smoking, compared to non-menthol smoking. Data from the government’s Population Assessment of Tobacco and Health (PATH) study shows that that youth menthol smokers have significantly higher levels of certain measures of dependence, and that initiation with a menthol-flavored cigarette is associated with a higher relative risk of continuing to daily smoking.

Menthol Cigarettes Reduce Smoking Cessation

Prohibiting menthol as a characterizing flavor in cigarettes has the potential to accelerate the decline in cigarette smoking in the United States. Cigarette sales data show that declines in menthol cigarette sales lag behind those of non-menthol cigarettes. From 2009 to 2018, sales of non-menthol cigarettes have declined by 33.1% nationally, while sales of menthol cigarettes have declined by only 8.2%. Of the decline in cigarette sales between 2009 and 2018, 91% is attributable to non-menthol cigarettes. Similarly, NSDUH data show that while overall cigarette smoking has been declining, the proportion of smokers using menthol cigarettes continues to increase. Overall, about 4 out of 10 (39.9%) smokers used menthol cigarettes in 2018, an increase from 34.7% in 2008-2010. By reducing smoking cessation, menthol has slowed the nation’s progress in reducing overall smoking.

---

The TPSAC and FDA Reports found that, in addition to increasing initiation of smoking among young people, menthol cigarettes are associated with reduced success in smoking cessation, particularly among African American smokers. The 2020 Surgeon General’s Report on smoking cessation, citing more recent evidence, concluded that the evidence is suggestive that restricting menthol products would lead to increased smoking cessation. Recent studies provide strong evidence of an association between menthol cigarette use and reduced cessation at the population level. An October 2020 study published in Nicotine & Tobacco Research represents one of the most robust longitudinal and nationally representative assessments of the relationship between menthol cigarette smoking and cessation. Analyzing four waves of data from the government’s nationally representative PATH survey, the study found that among daily smokers, menthol cigarette smokers have a 24% lower odds of quitting as compared to non-menthol smokers. Among daily smokers, African American menthol smokers had a 53% lower odds of quitting compared to African American non-menthol smokers and white menthol smokers had a 22% lower odds of quitting compared to white non-menthol smokers. While the study found no significant difference among quit rates for non-daily menthol and non-menthol smokers, the findings for daily smokers have greater implications for population health given that three-quarters (74.6%) of adult smokers are daily smokers. This study provides stronger evidence for the population level impact of menthol cigarettes on cessation than previous research from clinical trials, many of which have follow-up times as short as one month, and research from cessation clinic populations, which may not be generalizable to the full adult smoking population.

Menthol Cigarettes Have Contributed Significantly to Health Disparities

Prohibiting menthol as a characterizing flavor in cigarettes is not solely a public health issue; it is a social justice issue as well. The tobacco industry has targeted African American communities with advertising for menthol cigarettes for nearly 70 years. The tobacco industry has used multiple strategies and tactics to reach the African American population, including print media, in-store advertising, community and music events, distribution of free cigarettes from mobile vans, and specialized promotions. The legacy of this advertising is reflected in the continued high prevalence of menthol cigarette use among African American smokers. According to 2018 NSDUH data, 85% of African American smokers smoke menthols, compared to just 29% of White smokers. Preference for menthol is also disproportionately high among lesbian, gay, and bisexual smokers, smokers with mental health problems, socioeconomically disadvantaged populations, and pregnant women.

The high rates of menthol smoking result in a disproportionate burden of tobacco-related death and disease among African Americans due to menthol’s role in decreasing cessation. This is despite high motivation to quit among African American smokers, who are more likely to have made a quit attempt

13 TPSAC Menthol Report; FDA Report.
17 TPSAC Menthol Report.
and used counseling services in the previous year than White smokers. In its 2011 report to FDA, TPSAC estimated that by 2020, 4,700 excess deaths among African Americans would be attributable to menthol cigarettes. Research continues to support menthol’s role in tobacco-related health disparities. A recent meta-analysis found that among African Americans, menthol smokers have a 12% lower odds of smoking cessation compared to non-menthol smokers and, as noted above, PATH data show that among daily smokers, African American menthol smokers have a 53% lower odds of quitting compared to African American non-menthol cigarette smokers.

**Menthol Bans Have Been Shown to Increase Smoking Cessation in Canada**

The likelihood of increasing quitting following a menthol ban is supported by the recent real-world experience of Canada, which in October, 2017, became the first country to implement a total ban on menthol cigarettes. This nationwide ban came after most provinces had already banned them. Surveillance data from the province of Ontario, which banned menthol cigarettes in January, 2017, showed an increase in quit attempts and cessation one year after the ban. Two years later, a follow-up survey found that both daily and occasional menthol smokers were more likely than non-menthol smokers to report having quit smoking for six months (18% and 15%, vs. 7%) or having made a quit attempt (72% and 74%, vs. 58%).

Findings on the impact of the Canadian menthol bans on additional Canadian provinces is also starting to emerge. The International Tobacco Control Policy Evaluation Project (ITC) conducted a longitudinal national survey of Canadian smokers and found that after the implementation of menthol bans in seven provinces, menthol smokers were significantly more likely to try to quit than non-menthol smokers (60% vs. 48%), and were twice as likely to have quit smoking for at least six months (12% vs. 6%), and the ban had the same benefits across the provinces. While Canada is not the US, the experience in Canada suggest that a ban on menthol would increase cessation in the US. In fact, the

---

21 TPSAC Menthol Report.
benefit might be greater than seen in Canada because more US smokers report intending to quit in the event of a ban than was true in Canada.\textsuperscript{27}

A recent review also supports increased cessation consequent to a menthol ban. Cadham et al.\textsuperscript{28} identified 24 studies on the potential impact of menthol bans, concluding that “extending the US cigarette flavor ban to menthol products would promote smoking cessation and reduce initiation.”

Conclusion

The evidence available at the time of the 2013 Citizen Petition was sufficient to support a prohibition on the use of menthol as a characterizing flavor in cigarettes and the evidence base justifying such action is only more robust today. A science-based decision on the Citizen Petition must conclude that there is no public health justification for continued availability of menthol cigarettes.

Respectfully submitted,

Jonathan M. Samet, MD, MS
Dean and Professor
Colorado School of Public Health

Matthew L. Myers
President
Campaign for Tobacco-Free Kids

Jessica Barrington-Trimis, PhD
Assistant Professor of Preventive Medicine
University of Southern California
Director, USC Epidemiology of Substance Use (EOS) Research Group

Alexis Barton, PhD
Research Manager, Truth Initiative Schroeder Institute®

Mary T Bassett, MD, MPH
Director, François-Xavier Bagnoud Center for Health and Human Rights
Harvard University

Neal L. Benowitz, MD
Professor of Medicine Emeritus (Active)
University of California San Francisco
Zuckerberg San Francisco General Hospital

Otis W. Brawley, MD, MACP
Johns Hopkins School of Medicine and
Johns Hopkins Bloomberg School of Public Health

Michael O. Chaiton, PhD
Scientist
Centre for Addiction and Mental Health
Toronto, Canada

Frank Chaloupka, PhD
Institute for Health Research and Policy
Director, Health Policy Center
University of Illinois at Chicago

Joanna Cohen, PhD
Director, Institute for Global Tobacco Control
Bloomberg Professor of Disease Prevention
Department of Health, Behavior and Society
Johns Hopkins Bloomberg School of Public Health

Sue Curry, PhD
Dean Emerita and Distinguished Professor of Health Management and Policy
College of Public Health
University of Iowa


Joanne D’Silva, PhD, MPH
Director of Health Equity Research
Clearway, Minnesota

Cristine Delnevo, PhD, MPH, FAAHB
Professor
Director, Center for Tobacco Studies
Co-Leader of the Cancer Prevention and Control Program at the Rutgers Cancer Institute of New Jersey

Elizabeth Do, PhD, MPH
Research Manager, Truth Initiative Schroeder Institute®

Michael Eriksen, ScD
Regents’ Professor
Former and Founding Dean
School of Public Health
Georgia State University

Pebbles Fagan, PhD, MPH
Professor and Director
Tobacco Prevention and Control Expert

Michael C. Fiore, MD, MPH, MBA
University of Wisconsin Hilldale Professor of Medicine
Director, Center for Tobacco Research and Intervention (UW-CTRI)
University of Wisconsin School of Medicine and Public Health
Member, National Academy of Medicine

Geoffrey T. Fong, PhD, FRSC, FCAHS
Professor of Psychology and Public Health and Health Systems, University of Waterloo
Senior Investigator, Ontario Institute for Cancer Research

Daniel P. Giovenco, PhD, MPH
Assistant Professor, Department of Sociomedical Sciences
Columbia University Mailman School of Public Health

Gary Giovino, PhD, MS
School of Public Health and Health Professions
University at Buffalo, SUNY

Elizabeth C. Hair, PhD
Senior Vice President, Truth Initiative Schroeder Institute®

Bonnie Halpern-Felsher, PhD, FSAHM
Professor of Pediatrics, Adolescent Medicine
Stanford University
Founder and Executive Director of the Stanford Tobacco Prevention Toolkit

Dorothy K. Hatsukami, PhD
Professor of Psychiatry and Behavioral Sciences
Forster Family Chair in Cancer Prevention
Associate Director, Masonic Cancer Center
University of Minnesota

Stephen S. Hecht, PhD
Wallin Professor of Cancer Prevention
American Cancer Society Professor
American Chemical Society Fellow
Masonic Cancer Center
University of Minnesota

Patricia Nez Henderson, MD, MPH
Black Hills Center for American Indian Health

Lisa Henriksen, PhD
Stanford University School of Medicine

Howard K. Koh, MD, MPH
Harvey V. Fineberg Professor of the Practice of Public Health Leadership
Harvard T.H. Chan School of Public Health
Harvard Kennedy School

Jennifer Kreslak, PhD, MPH
Research Director, Truth Initiative Schroeder Institute®

Suchitra Krishnan-Sarin, PhD
Professor of Psychiatry
Chair, Human Investigations Committee II
Yale University School of Medicine

Adam Leventhal, PhD
Director, USC Institute for Addiction Science and Health, Emotion, & Addiction Laboratory
USC Norris Comprehensive Cancer Center
Keck School of Medicine
University of Southern California
Pamela Ling, MD MPH  
Professor, Department of Medicine  
Director, Tobacco Control Research Fellowship  
Interim Director, Center for Tobacco Control Research and Education  
University of California San Francisco

Ruth E. Malone, RN, PhD  
Professor Emerita (Recalled)  
Department of Social and Behavioral Sciences  
School of Nursing  
University of California, San Francisco  
Editor-in-Chief, Tobacco Control

David Mendez, PhD  
School of Public Health  
University of Michigan

Sarah D. Mills, PhD, MPH  
Assistant Professor  
Department of Health Behavior  
Gillings School of Global Public Health  
University of North Carolina, Chapel Hill

Minal Patel, PhD, MPH  
Director, Truth Initiative Schroeder Institute®

Lucy Popova, PhD  
Assistant Professor  
Second Century Initiative (2CI) Scholar  
Department of Health Policy and Behavioral Sciences  
School of Public Health | Georgia State University

Judith J. Prochaska, PhD, MPH  
Professor of Medicine  
Deputy Director, Stanford Prevention Research Center  
Department of Medicine | Stanford University

Robert N. Proctor, PhD, MS  
Professor of the History of Science and Professor, by courtesy, of Pulmonary Medicine  
Stanford University

Jessica Rath, PhD, MPH, CHES  
Managing Director, Truth Initiative Schroeder Institute®

Kurt M. Ribisl, PhD  
Jo Anne Earp Distinguished Professor and Chair  
Department of Health Behavior  
UNC Gillings School of Global Public Health

Shyanika Wijesinha Rose, PhD MA  
Assistant Professor, Department of Behavioral Science  
University of Kentucky, College of Medicine  
Center for Health Equity Transformation (CHET)

Barbara Schillo, PhD  
Vice President, Truth Initiative Schroeder Institute®

Steven A. Schroeder, MD  
Distinguished Professor of Health and Healthcare  
Director, Smoking Cessation Leadership Center  
Department of Medicine  
University of California, San Francisco

Peter G. Shields, M.D.  
Deputy Director, Comprehensive Cancer Center  
Professor, College of Medicine  
Julius F. Stone Chair in Cancer Research  
James Cancer Hospital  
The Ohio State University Wexner Medical Center

Philip H. Smith, PhD  
Assistant Professor of Public Health  
Miami University

Donna Vallone, PhD, MPH  
Chief Research Officer, Truth Initiative Schroeder Institute®  
Associate Professor (Adjunct)  
College of Global Public Health  
New York University

cc: Mitch Zeller, JD, Director - Center for Tobacco Products